title: A USA registry of gastrointestinal stromal tumor patients: changes in practice over time and differences between community and academic practices.
abstract: BACKGROUND
  The objective of the study was to describe patterns of care of patients with gastrointestinal stromal tumors (GISTs) in the United States in the tyrosine kinase inhibitor (TKI) era.
  
  
  METHODS
  From November 2004 through March 2009, data were collected regarding demographics, diagnostic history, treatment, relapse, and survival of 882 patients with GIST from 122 community and academic medical practices.
  
  
  RESULTS
  The most common first-line treatment for the 719 patients presenting with localized GIST was surgery (87%). Use of adjuvant imatinib increased after June 2007; 47% of patients enrolled in the registry considered by the investigator to be at high risk for recurrence received adjuvant imatinib after June 2007 versus 18% before. Overall, 56% of patients received imatinib and 11% received sunitinib. The utilization of targeted therapy increased over time (45% and 0.4% of patients received imatinib and sunitinib, respectively, in 2006 versus 56% and 11%, respectively, in 2009).
  
  
  CONCLUSIONS
  These are the first GIST registry data from the TKI era. The use of targeted therapy for GIST has increased in accordance with updated treatment guidelines. Diagnosis of GIST has evolved with increased use of KIT testing. The duration of targeted therapy in the adjuvant therapy setting is similar in community and academic practices.
authors.affiliation: Department of Surgical Oncology, Sarcoma Research Center at the University of Texas MD Anderson Cancer Center, Houston, USA.
authors.forename: P W T
authors.initials: PWT
authors.lastname: Pisters
authors.affiliation: Division of Medical Oncology, University of British Columbia, Vancouver, Canada.
authors.forename: C D
authors.initials: CD
authors.lastname: Blanke
authors.affiliation: Department of Medical Oncology, Sarcoma Program, Fox Chase Cancer Center, Philadelphia. Electronic address: margaret.vonmehren@fccc.edu.
authors.forename: M
authors.initials: M
authors.lastname: von Mehren
authors.affiliation: Division of Oncology, Medical Oncology Section, Washington University, St Louis.
authors.forename: J
authors.initials: J
authors.lastname: Picus
authors.affiliation: Novartis Pharmaceuticals Corp., East Hanover.
authors.forename: A
authors.initials: A
authors.lastname: Sirulnik
authors.affiliation: Novartis Pharmaceuticals Corp., East Hanover.
authors.forename: E
authors.initials: E
authors.lastname: Stealey
authors.affiliation: Department of Medical Oncology, Sarcoma Research Center at The University of Texas MD Anderson Cancer Center, Houston, USA.
authors.forename: J C
authors.initials: JC
authors.lastname: Trent
mesh_terms: D000046:Academic Medical Centers; D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001549:Benzamides; D005260:Female; D005770:Gastrointestinal Neoplasms / Q000175:diagnosis* / Q000188:drug therapy / Q000453:epidemiology / Q000628:therapy*; D046152:Gastrointestinal Stromal Tumors / Q000175:diagnosis* / Q000188:drug therapy / Q000453:epidemiology / Q000628:therapy*; D006764:Hospitals, Community; D006801:Humans; D000068877:Imatinib Mesylate; D007211:Indoles / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D058990:Molecular Targeted Therapy; D010879:Piperazines / Q000627:therapeutic use; D010818:Practice Patterns, Physicians'; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors; D011743:Pyrimidines / Q000627:therapeutic use; D011758:Pyrroles / Q000627:therapeutic use; D012042:Registries; D000077210:Sunitinib; D014481:United States / Q000453:epidemiology; D055815:Young Adult
chemical_list: D001549:Benzamides; D007211:Indoles; D010879:Piperazines; D011743:Pyrimidines; D011758:Pyrroles; D000068877:Imatinib Mesylate; D011505:Protein-Tyrosine Kinases; D000077210:Sunitinib